tbuckley/cabot-search huggingface dataset:
Connect MM®—the Multiple Myeloma (MM) Disease Registry: Incidence of Second Primary Malignancies (SPM)
Authors: Robert M. Rifkin, Rafat Abonour, Jatin J. Shah, Jayesh Mehta, Mohit Narang, Howard R. Terebelo, Cristina J Gasparetto, Sachdev P. Thomas, Kathleen Toomey, James W Hardin, Jane Jie Lu, Laurie Kenvin, Shankar Srinivasan, Rosanna J. Ricafort, Yasir Nagarwala, Brian G. M. Durie
Journal: Blood (2014)
Re: Jaimin R. Bhatt, Patrick O. Richard, Nicole S. Kim, et al. Natural History of Renal Angiomyolipoma (AML): Most Patients with Large AMLs &gt;4 cm Can Be Offered Active Surveillance as an Initial Management Strategy. Eur Urol 2016;70:85–90
Authors: Yi Cai, Hanzhong Li, Yushi Zhang
Journal: European Urology (2016)
In Vitro and In Vivo Evidences of Osteocyte Involvement In Myeloma-Induced Osteolysis
Authors: Nicola Giuliani, Paola Storti, Manuela Abeltino, Marina Bolzoni, Marzia Ferretti, Mirca Lazzaretti, Benedetta Dalla Palma, Katia Todoerti, Eugenia Martella, Luca Agnelli, Antonino Neri, Vittorio Rizzoli, Carla Palumbo
Journal: Blood (2010)
Donor Bone Marrow Derived IL-17 Expressing Cells Exacerbate Chronic Graft-Versus-Host Disease in a Murine Bone Marrow Transplantation.
Authors: Rie Kuroda, Ryosei Nishimura, Katsuaki Sato, Hideaki Maeba, Kazuhito Naka, Yo Niida, Raita Araki, Yoichiro Iwakura, Shoichi Koizumi, Akihiro Yachie
Journal: Blood (2008)
Active Surveillance for Low-Risk Prostate Cancer—An Evolving International Standard of Care
Authors: Matthew R. Cooperberg
Journal: JAMA Oncology (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Oncology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Oncology journal
Influence of Cytogenetics in Patients with Relapsed and Refractory Multiple Myeloma (MM) Treated with Carfilzomib (CFZ).
Authors: Andrzej Jakubowiak, Luhua Wang, Robert Z Orlowski, Sundar Jagannath, David Siegel, A. Keith Stewart, Vishal Kukreti, Sagar Lonial, Kevin T. McDonagh, Marcy Vallone, Michael Kauffman, Ravi Vij
Journal: Blood (2009)
Improvements in Skeletal Manifestations in Gaucher Disease Type 1 Patients After 3 Years of Treatment with Oral Eliglustat During a Phase 2 Trial,
Authors: M. Judith Peterschmitt, Ravi S Kamath, Elena Lukina, Nora Watman, Marta Dragosky, Marcelo Iastrebner, Gregory M Pastores, Elsa Avila Arreguin, Mici Phillips, Hanna Rosenbaum, Elena Sysoeva, Rasha Aguzzi, Leorah H Ross, Ana Cristina Puga, Daniel I Rosenthal
Journal: Blood (2011)
Use of a comprehensive geriatric assessment (CGA) to guide the use of sorafenib in unfit elderly patients (EP) with metastatic renal cell carcinoma (RCC).
Authors: L. Fratino, A. Bearz, J. Polesel, C. Lestuzzi, E. Vaccher, U. Tirelli
Journal: Journal of Clinical Oncology (2010)

e19636 Background: EP are a large portion of cancer patients but few of them have access to optimal treatments, including EP affected by advanced or metastatic RCC. CGA is an essential tool to plan cancer treatment in EP, being a milestone in screening process and decision-making. The introduction into clinical practice of multi kinase inhibitors (MTKIs) can represent a new therapeutic option for EP. The present study assessed the use of Sorafenib in EP according to CGA. Methods: EP affected by metastatic RCC were routinely evaluated by means of CGA and classified in three risk groups: Fit, Unfit, and Frail. Unfit EP were those with mild co-morbidity or functionally mild disabled (e.g. ADL <5 and/or IADL ≤ 5); Frail EP were aged>80 years (chronologically frails) or <80 years with severe co-morbidity and/or higly disabled (functionally frails). The remaining were Fit EP. Fit and unfit and chronologically frail EP underwent therapy with Sorafenib, whereas functionally frail EP underwent best supportive care. Sorafenib was given 400mg bid; dose interruption was allowed if grade 3 toxicity occurred. Biochemical and immunological, serum VEGF and bFGF assessment were performed at baseline and during therapy. Results: 23 EP were evaluated over the study period: 67% was unfit and 13% frail according to CGA definition. Their median age was 74 years (range 68-82); 75% was affected by one or more co-morbidities that required daily treatment. 19/23 started Sorafenib treatment (800 mg/die; median duration 10 weeks), 2 EP were frail and underwent best supportive care, 2 refused therapy. 12 EP needed therapy discontinuation, while 10 needed dose reduction. The most common toxicities were: fatigue (G3), mucosities (G2), hypertension (G1-2). Among treated EP, 60.5% was alive after 12 months. Conclusions: Our experience showed that even in unfit EP Sorafenib treatment might be consider a safe and efficacious treatment option. This observation, though based on a small number of patients, suggest that EP must not be denied biological therapies because of their age. No significant financial relationships to disclose.
Prostate-specific antigen doubling time as a predictor of prostate cancer disease progression and survival
Authors: J. B. Nelson, A. R. Allen, S. M. Hulting, J. D. Isaacson, D. S. Sleep
Journal: Journal of Clinical Oncology (2004)

4554 Background: Prostate-specific antigen doubling time (PSADT) has been identified as a predictor of outcome in prostate cancer. Atrasentan, a potent, selective, oral endothelin A receptor antagonist, significantly decreased time to prostate-specific antigen (PSA) progression in a randomized, double-blind, placebo-controlled phase 2 trial in 271 men with metastatic HRPC. In that study, PSADT <4 mo was predictive of rapid disease progression and decreased survival in men with metastatic hormone-refractory prostate cancer (HRPC). Our objective was to confirm the utility of PSADT as a predictor of disease progression and survival in a larger population of subjects from combined phase 2 and 3 trials. Methods: Data from randomized, double-blind, placebo-controlled phase 2 and 3 trials of metastatic HRPC patients given either placebo or atrasentan (10 or 2.5 mg QD) were combined. Measurements from 982 patients with a minimum of 3 PSA values on treatment were analyzed. Data from all treatment arms were pooled and stratified by PSADT <4 mo vs ≥4 mo. Kaplan-Meier and Cox proportional hazard methodologies were used to compare time to disease progression (TTP) and survival between the PSADT <4 mo and PSADT ≥4 mo groups. Results: 982 patients were included in the analyses: 484 patients had a PSADT <4 mo and 498 had a PSADT ≥4 mo. Patients with a PSADT ≥4 mo showed a statistically significant longer median TTP (178 days), more than twofold greater than those with a PSADT <4 mo (85 days, log-rank p<0.001). Survival in patients with a PSADT <4 mo was significantly shorter than that in patients with a PSADT ≥4 mo (log-rank p<0.001). Median survival was 445 days for patients with PSADT <4 mo vs 746 days for patients with PSADT ≥4 mo. Conclusions: These data confirm earlier findings that a PSADT <4 mo is predictive of early disease progression and reduced survival of men with metastatic HRPC, independent of therapy. Author Disclosure Employment or Leadership Consultant or Advisory Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration Abbott Laboratories Abbott Laboratories Abbott Laboratories
p210BCR-ABL by down Regulating FLI-1 Reprograms Megakaryocytic Progenitors to the Erythroid Lineage.
Authors: Dorothée Buet, Hana Raslova, Gaëtan Juban, Jean-François Geay, Peggy Jarrier, Ali G. Turhan, François Morle, William Vainchenker, Fawzia Louache
Journal: Blood (2005)
GW26-e0674 The Arterial Stiffness Assessment In An Abdominal Aorta Aneurysm Model Of Rat By Pulse Wave Velocity In Vivo
Authors: Pingping Ren, Qunying Li, Li Zhang, Wei Han, Peige Zhang, Jing Wang, Mingxing Xie
Journal: Journal of the American College of Cardiology (2015)
Abstract 10120: Go Red for Women Cardiovascular Health Screening Evaluation: The Dichotomy Between Awareness and Perception of Cardiovascular Risk in the Community
Authors: Juliana M Kling, Virginia M Miller, Rekha Mankad, Susan Wilansky, Qing Wu, Sharon L Mulvagh
Journal: Circulation (2011)

Background: Cardiovascular (CV) disease remains the leading cause of death in American women and affects more than one in three in the United States. Research shows that women are becoming more aware of their existing and potential CV disease burden as well as the preventive actions to reduce CV risk. However, there remains a dichotomy between awareness and perceived risk. We sought to further characterize this awareness gap in women attracted to an annual CV health screening and educational event in order to improve strategies to increase CV health and reduce risk. Methods: During an annual CV health screening event in Rochester, Minnesota, 294 women were surveyed over four years. Surveys collected detailed information from participants regarding knowledge of CV disease, their CV risk factors, and their perceived risk. Biochemical (lipids, glucose), morphometric (BMI) and hemodynamic (BP) measurements were also obtained. Levels of risk were determined from the recently published 2011 American Heart Assoc...
Survival of resectable pancreatic cancer patients with diabetes
Authors: N. L. Busaidy, C. F. Yazbeck, P. Shah, D. B. Evans, D. Li, J. M. Geraci, M. A. Weiser
Journal: Journal of Clinical Oncology (2006)

4098 Background: Pancreatic cancer is the fourth leading cause of cancer mortality in the United States. Determining modifiable prognostic factors may be a key step in improving outcomes of these patients with overall poor survival. Pancreatic adenocarcinoma is often associated with diabetes. Our aim is to determine whether diabetes worsens disease specific mortality in resectable pancreatic cancer patients. Methods: In this study, we reviewed 298 patients with resected pancreatic adenocarcinoma in our surgical database at MD Anderson Cancer Center between August 1992 and July 2003. Patients were classified into diabetics (N = 87) (defined as those carrying the diagnosis of diabetes (DM) at time of presentation or on long term therapy for DM) and nondiabetics (N = 211). Univariate (log-rank) and Multivariate (Cox Regression) analyses were performed. Results: Compared to nondiabetics, patients with DM had a poorer overall survival with a median survival of 19.8 vs 29.2 months (p = 0.01). On multivariate analysis, correcting for known poor prognosticators in resectable patients: staging, histologic tumor differentiation and retroperitoneal margin status, diabetes was a significant independent risk factor for increased overall mortality (OR 1.55, 95% CI 1.15–2.07, p = 0.004). Disease-specific mortality was also higher in diabetics vs. non-diabetics with a median survival of 29.87 vs. 21.47 months (OR 1.37 95% CI 1.00–1.89 p = 0.048). Stage specific mortality was also higher among diabetics. Potential etiologies will be discussed. Conclusions: Diabetes worsens disease specific and overall mortality in patients with pancreatic cancer. Diabetes may be a modifiable risk factor and should be considered while prognosticating patients with resectable pancreatic cancer. Further studies are needed to determine whether treatment of diabetes improves outcomes. No significant financial relationships to disclose.
Phase I/II trial of ruxolitinib in combination with trastuzumab in metastatic HER2-positive breast cancer.
Authors: Kevin Kalinsky, Dow-Chung Chi, Shing Mirn Lee, Kerin B. Adelson, Katherine D. Crew, Ellen Chuang, Della Makower, Dawn L. Hershman, Andrea Califano, Jose Silva, Matthew A. Maurer
Journal: Journal of Clinical Oncology (2014)

TPS666 Background: Integrated analysis of whole genome RNAi screening with computationally reverse engineered interactome models identified IL6/JAK/STAT as a master regulator pathway essential for growth of ErbB2/HER2 positive breast cancer. Ruxolitinib (R), FDA-approved treatment for myelofibrosis, inhibits JAK1 and JAK2. The combination of R plus Trastuzumab (T) is synergistic in tumor growth inhibition in mouse xenografts of HER2 amplified breast cancer cell lines. These data provide a strong rationale for studying the efficacy of combination R and T in a clinical trial. Methods: A multi-center, open-label, phase I/II (P1/2) trial of R plus T in HER2+ metastatic breast cancer (MBC) who have progressed on T-based therapy. P1 will be an adaptive design with 10 patients, using the time-to-event continual reassessment method. The recommended P2 dose (RP2D) will be used in a non-randomized, open-label P2 trial with 30 evaluable patients. Given the anticipated limited overlapping toxicities, 33 patients are expected for the P1/2 (range: 33-42 pts). The duration of a treatment cycle will be 21 days. R will be taken orally twice a day continuously. The P1 dosing range will be 10-25 mg BID. T will be administered on Day 1 of each cycle at standard dosing. The primary endpoint is progression-free survival (PFS). Assuming a historical PFS of 8 weeks with single-agent agent HER2-targeted therapy in HER2+ MBC after progressing on T-based therapy, we predict that patients receiving the combination of R plus T will have a PFS of at least 13 weeks. With a 2-sided alpha of 0.05, we have 80% power to detect a difference with 30 pts. Objective Response Rate (ORR) will be assessed by imaging every 9 weeks. Blood samples will be obtained for biomarker analysis pre-treatment, on-treatment on cycle 2 day 1, and then at progression. Pre-treatment biopsies from archival tissue or new biopsy, prior to cycle 2 day 1, and upon progression of disease will be discussed with pts with accessible disease. Predictive markers include tumor pSTAT3 expression(tumor), tumor gene expression, and serum IL-6, IL-8, and C-reactive protein.
Pre-Clinical Investigation of Targeted Therapies for Double Hit Diffuse Large B-Cell Lymphoma (DH-DLBCL)
Authors: Priyank P. Patel, Alison Zeccola, Vishala T. Neppalli, Juan J Gu, Cory Mavis, Sheila Sait, Francisco J. Hernandez-Ilizaliturri
Journal: Blood (2015)
Phase I/II trial of cabazitaxel plus abiraterone in patients with metastatic castration-resistant prostate cancer (mCRPC) progressing after docetaxel and abiraterone
Authors: C. Massard, J. Mateo, Y. Loriot, C. Pezaro, L. Albiges, N. Mehra, A. Varga, D. Bianchini, C.J. Ryan, D.P. Petrylak, G. Attard, L. Shen, K. Fizazi, J. de Bono
Journal: Annals of Oncology (2016)

Abiraterone and cabazitaxel improve survival in patients with metastatic castration-resistant prostate cancer (mCRPC). We conducted an open-label phase I/II trial of cabazitaxel plus abiraterone to assess the antitumor activity and tolerability in patients with progressive mCRPC after docetaxel (phase I), and after docetaxel and abiraterone (phase II) (NCT01511536).The primary objectives were to determine the maximum tolerated dose (MTD) and dose-limiting toxicities (DLTs) of cabazitaxel plus abiraterone (phase I), and the prostate-specific antigen (PSA) response defined as a ≥ 50% decrease confirmed ≥3 weeks later with this combination (phase II).Ten patients were enrolled in the phase I component; nine were evaluable. No DLTs were identified. The MTD was established as the approved doses for both drugs (cabazitaxel 25 mg/m2 every 3 weeks and abiraterone 1000 mg once daily). Daily abiraterone treatment did not impact on cabazitaxel clearance. Twenty-seven patients received cabazitaxel plus abiraterone plus prednisone (5 mg twice daily) in phase II. The median number of cycles administered (cabazitaxel) was seven (range: 1-28). Grade 3-4 treatment-emergent adverse events included asthenia (in 5 patients; 14%), neutropenia (in 5 patients; 14%) and diarrhea (in 3 patients; 8%). Nine patients (24%) required dose reductions of cabazitaxel. Of 26 evaluable patients, 12 achieved a PSA response [46%; 95% confidence interval (CI): 26.6-66.6%]. Median PSA-progression-free survival was 6.9 months (95% CI: 4.1-10.3 months). Of 14 patients with measurable disease at baseline, 3 (21%) achieved a partial response per response evaluation criteria in solid tumors.The combination of cabazitaxel and abiraterone has a manageable safety profile and shows antitumor activity in patients previously treated with docetaxel and abiraterone.
A phase IV, open-label trial using bortezomib for retreatment of patients (pts) with multiple myeloma (MM) following an initial response to bortezomib
Authors: M. Druck, I. B. Walters, H. Carloss, R. Sood, A. L. Leblanc, S. J. Noga
Journal: Journal of Clinical Oncology (2006)

17539 Background: Bortezomib (VELCADE; Vc) has substantial single agent activity in heavily pretreated patients. Response rates have been shown to improve when used in combination with other agents. Since some pts experience long durations of response with treatment-free periods, this open-label, single-arm study was designed to determine the utility of retreatment with Vc alone or in combination with dexamethasone, thalidomide or liposomal doxorubicin. Methods: Pts who previously responded to Vc alone or in combination are eligible for this study. Up to 78 pts will receive Vc alone or in combination at the finishing dose of their initial Vc treatment (0.7, 1.0, or 1.3 mg/m 2 ) as a bolus, intravenous injection on days 1, 4, 8, and 11 of a 21-day treatment cycle. Responses are assessed by the investigators and also calculated from percentage reduction in serum or urine M-protein. Results: To date, 15 pts have been treated and 12 are evaluable for response (having received at least 2 cycles of therapy). 8/12 patients had dexamethasone added to their regimen. The population is representative of pts with relapsed and refractory MM: mean age, 68 years; 4 males, 8 females; median of 5 prior lines of therapy; and 67% IgG MM. Median treatment-free period between the end of first Vc treatment and the start of retreatment: 11.1 months (range 5–21 months). Investigator-assessed responses show that 50% of pts have achieved a PR or CR. Only 1 pt had progressive disease. One pt has developed new peripheral neuropathy, while pre-existing neuropathy has worsened in 4 pts. No Vc-related serious adverse events have been reported. Conclusions: Preliminary results show that retreatment with Vc alone or in combination has encouraging activity with manageable toxicity even in pts who are heavily pretreated. These data suggest that repeated use after a treatment break may achieve prolonged disease control. This is the first report of Vc retreatment for MM. [Table: see text]
Decreased Relapse Rates without Excessive Transplant Related Mortality Following Cord Blood Transplantation (CBT): A Matched Cohort Analysis Comparing Myeloablative Cord, Matched Unrelated, and Mismatched Unrelated Donor Transplants.
Authors: Jonathan A Gutman, Wendy Leisenring, Frederick R. Appelbaum, Ann E Woolfrey, Colleen Delaney
Journal: Blood (2008)
Transcription Factors PU.1 and EGR2 Inhibits the Oncogenic Microrna Cluster Mir-17-92 during Macrophage Differentiation
Authors: Vit Pospisil, Karin Vargova, Pavel Burda, Juraj Kokavec, Emanuel Necas, Jiri Zavadil, Tomas Stopka
Journal: Blood (2008)
Has the Prognostic of Primary Plasma Cell Leukemia Improved with New drugs?
Authors: Driss Chaoui, Xavier Leleu, Murielle Roussel, Bruno Royer, Marie-therese Rubio, Sophie Ducastelle, Fatiha Merabet, Laurent Garderet, Brigitte Kolb, Houria Debarri, Yazid Arkam, Jean-Luc Harousseau, Philippe Moreau
Journal: Blood (2009)
Circulating Nucleosomes and Neutrophil Activation As Risk Factors for Deep Vein Thrombosis
Authors: Maurits L van Montfoort, Femke Stephan, Mandy N Lauw, Barbara A Hutten, Gerard J van Mierlo, Shabnam Solati, Saskia Middeldorp, Joost CM Meijers, Sacha S Zeerleder
Journal: Blood (2012)
Cloning of Idiotype Immunoglobulin Genes in B Cell Lymphomas by Anchored PCR and Production of Individual Recombinant Idiotype Vaccines in E. coli.
Authors: Cristina Bertinetti, Frederic Simon, Jana Reinhardt, Katja Mauerer, Kristina Mikesch, Felicia M. Rosenthal, Hendrik Veelken
Journal: Blood (2005)
Whole Body (WB) MRI in Newly Diagnosed Multiple Myeloma (MM): Fat Fraction Changes at 8 Weeks Predict Response to Induction with Bortezomib Regimens
Authors: Arash Latifoltojar, Kwee L Yong, Margaret Hall-Craggs, Neil Rabin, Rakesh Popat, Alan Bainbridge, Magdalena Sokolska, Nikolaos Dikaios, Shirley D'Sa, Ali Rismani, Shonit Punwani
Journal: Blood (2015)
Proposal of a new staging system for hepatocellular carcinoma based on the treatment strategy: An analysis of 1,084 patients
Authors: H. Ishii, J. Furuse, T. Kinoshita, K. Nakachi, E. Suzuki, M. Yoshino, M. Konishi, T. Nakagohri, S. Takahashi, N. Gotohda
Journal: Journal of Clinical Oncology (2006)

4137 Background: Although several prognostic models have been proposed for hepatocellular carcinoma (HCC), they are not useful for conducting treatment strategy. Methods: Between July 1992 and May 2005, consecutive 1084 patients (pts) with naïve HCC were treated in our hospital. Based on our treatment strategy, we set our own HCC stage as follows: stage 1; Child-Pugh A or B, N0M0, solitary tumor without vascular invasion (VI), stage 2; Child-Pugh A or B, N0M0, multiple tumors without VI, stage 3; Child-Pugh A or B, N0M0, solitary tumor with VI, stage 4A; Child-Pugh A or B, N0M0, multiple tumors with VI, stage 4B; Child-Pugh A or B, N1 or M1, any T, stage 4C; Child-Pugh C, any TNM. Generally, treatments for stage 4C, 4B, &amp; 4A were observation, chemotherapy trials or aggressive local therapies in selected pts, &amp; hepatic arterial infusion chemotherapy. For the pts with stage 1–3, the priority of treatment options was hepatectomy first, percutaneous ablation (PA) second, and transcatheter arterial chemoembolization third. PA was indicated for 3 or fewer HCC nodules without VI, of which the largest diameter were smaller than 3 cm. Treatment outcomes were retrospectively analyzed according to the above staging system. Results: The overall survival rate was 50% at 3 yrs, 33% at 5 yrs, 24% at 7 yrs &amp; 13% at 10 yrs. The median survival in stage 1, 2, 3, 4A, 4B &amp; 4C was 5.5 yrs (N = 444), 2.9 yrs (N = 397), 0.8 yr (N = 36), 0.5 yr (N = 109), 0.3 yr (N = 76) &amp; 0.2 yr (N = 22), respectively. Most of the definitive local therapy (91% of 371 hepatectomies with curative intent &amp; 99% of 191 PAs) were classified in stage 1 or 2. The prognosis was also well predicted by the other 6 staging systems (Okuda, AJCC, CLIP, JIS, Tokyo and BCLC). However, hepatectomy with curative intent &amp; PA were distributed into a CLIP score of 0–5 &amp; 0–3, respectively, &amp; into a JIS score of 0–4 &amp; 0–3, respectively. Conclusions: The present staging system was simple &amp; predicted prognosis well. Although other scoring systems caused various heterogeneities (hepatic reserve &amp; tumor status) in each score, our staging system consisted of homogenous hepatic reserve &amp; simple tumor status, so it might be useful for conducting treatment plan. Validation study is warranted in other population. No significant financial relationships to disclose.